Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
DARIOHEALTH CORP (DRIO)
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-11-04
$2.73-8.25%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for DRIO yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Manage debt and equity dilution carefully | A supporting condition in DARIOHEALTH CORP's published investment case. The stated target is No major new equity sales or debt increases. | Under Pressure | New large equity or debt issuance announced | New equity issuance of 2,437,060 shares vs no major new equity sales target Securities Purchase Agreement dated July 22, 2026, for the sale of 2,437,060 common shares to institutional investors. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making healthcare business, not a proven durable compounder. The multi-year view is intact, with recent financial performance still in the top half of its industry, but management execution is volatile and results have not yet shown clear progress on growth or margins.
The evidence describes DRIO as cheap versus peers, while the expectations gap is negative and the priced-in tag is justified, with low fragility. That points to modest market expectations, but confidence in the valuation assessment is only medium.
Near term, revenue and gross profit trends show limited progress: revenue fell from $7.6 million in 2024-Q4 to $5.2 million in 2026-Q2, while gross profit fell from $4.2 million to $3.2 million. Management is raising capital to fund working capital, investment, and acquisitions, but growth execution is mixed and margin progress is behind; erratic earnings and small-company risk remain concerns.
Over the next 1 to 3 years, the thesis hinges on whether commercial scaling and partnerships can restore revenue growth and whether gross margins improve. Near-term sector support depends in part on healthcare bellwethers continuing to report strong results; weaker jobs data or misses and lower guidance from those companies could weaken the sector backdrop.
The long-term thesis is intact but fragile at the business level: low peer valuation and a supportive sector backdrop are balanced by losses, weak margin progress, and volatile management. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Reduce EPS losses toward breakeven |
| A primary condition in DARIOHEALTH CORP's published investment case. The stated target is EPS loss narrows to less than -$0.50 per share. |
| Broken |
| EPS loss worsens beyond -$0.70 per share next year |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Sustain revenue growth near 49% next year | Analysts expect nearly 49% revenue growth next year. | Broken | YoY revenue growth falls below 30% next year | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.94 → $-2.52 · observed estimates
$0.04B → $0.03B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.94 | $38,225,667 | 2 / 2 |
| 2026-07-25 | $-1.94 | $38,225,667 | 2 / 2 |
| 2026-07-26 | $-1.94 | $38,225,667 | 2 / 2 |
| 2026-07-27 | $-1.94 | $38,225,667 | 2 / 2 |
| 2026-07-28 | $-0.68 | $38,772,000 | 2 / 3 |
| 2026-07-29 | $-1.94 | $38,225,667 | 2 / 2 |
| 2026-07-30 | $-0.68 | $37,329,000 | 2 / 4 |
| 2026-07-31 | $-1.94 | $38,225,667 | 2 / 3 |
| 2026-08-01 | $-1.94 | $38,225,667 | 2 / 3 |
| 2026-08-02 | $-0.68 | $37,329,000 | 2 / 4 |
| 2026-08-03 | $-0.68 | $37,329,000 | 2 / 4 |
| 2026-08-04 | $-0.68 | $37,329,000 | 2 / 4 |
| 2026-08-05 | $-0.68 | $37,329,000 | 2 / 4 |
| 2026-08-06 | $-1.94 | $38,225,667 | 2 / 3 |
| 2026-08-07 | $-1.94 | $38,225,667 | 2 / 3 |
| 2026-08-08 | $-0.68 | $37,329,000 | 2 / 4 |
| 2026-08-09 | $-0.68 | $37,329,000 | 2 / 4 |
| 2026-08-10 | $-0.68 | $37,329,000 | 2 / 4 |
| 2026-08-11 | $-0.68 | $37,329,000 | 2 / 4 |
| 2026-08-12 | $-1.94 | $38,225,667 | 2 / 3 |
| 2026-08-13 | $-0.68 | $37,329,000 | 2 / 4 |
| 2026-08-14 | $-1.94 | $38,225,667 | 2 / 3 |
| 2026-08-15 | $-1.94 | $38,225,667 | 2 / 3 |
| 2026-08-16 | $-1.94 | $38,225,667 | 2 / 3 |
| 2026-08-17 | $-1.94 | $38,225,667 | 2 / 3 |
| 2026-08-18 | $-1.94 | $38,225,667 | 2 / 3 |
| 2026-08-19 | $-1.94 | $38,225,667 | 2 / 3 |
| 2026-08-20 | $-2.47 | $31,425,333 | 2 / 3 |
| 2026-08-21 | $-2.25 | $31,083,750 | 2 / 3 |
| 2026-08-22 | $-2.25 | $31,083,750 | 2 / 3 |
| 2026-08-23 | $-2.25 | $31,083,750 | 2 / 3 |
| 2026-08-24 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-08-25 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-08-26 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-08-27 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-08-28 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-08-29 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-08-30 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-08-31 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-09-01 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-09-02 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-09-03 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-09-04 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-09-05 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-09-06 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-09-07 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-09-08 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-09-09 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-09-10 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-09-11 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-09-12 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-09-13 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-09-14 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-09-15 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-09-16 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-09-17 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-09-18 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-09-19 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-09-20 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-09-21 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-09-22 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-09-23 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-09-24 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-09-25 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-09-26 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-09-27 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-09-28 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-09-29 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-09-30 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-10-01 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-10-02 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-10-03 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-10-04 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-10-05 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-10-06 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-10-07 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-10-08 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-10-09 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-10-10 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-10-11 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-10-12 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-10-13 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-10-14 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-10-15 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-10-16 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-10-17 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-10-18 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-10-19 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-10-20 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-10-21 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-10-22 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-10-23 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-10-24 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-10-25 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-10-26 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-10-27 | $-2.52 | $28,111,667 | 2 / 3 |
| 2026-10-28 | $-2.52 | $27,357,500 | 2 / 4 |
| 2026-10-29 | $-2.52 | $27,357,500 | 2 / 4 |
| 2026-10-30 | $-2.52 | $27,357,500 | 2 / 4 |
| 2026-10-31 | $-2.52 | $27,357,500 | 2 / 4 |
| 2026-11-01 | $-2.52 | $27,357,500 | 2 / 4 |
| 2026-11-02 | $-2.52 | $27,357,500 | 2 / 4 |
| 2026-11-03 | $-2.52 | $27,357,500 | 2 / 4 |
| 2026-11-04 | $-2.52 | $27,357,500 | 2 / 4 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 5 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.